Vogenx (VOGX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel therapies for metabolic diseases, including post-bariatric hypoglycemia (PBH), gastroparesis, and GIP-dependent Cushing's Syndrome.

• Lead candidate mizagliflozin is a selective SGLT1 inhibitor, licensed globally (excluding Japan, Korea, Taiwan) from Kissei, targeting glucose absorption disorders.

• Pipeline includes VGX-2857 for weight maintenance and early discovery efforts in solute carrier biology for broader metabolic, neurologic, oncologic, and cardiovascular indications.

• Business strategy centers on advancing clinical programs, building internal discovery capabilities, and selectively pursuing strategic partnerships.

Financial performance and metrics

• No revenue from product sales to date; operations funded primarily through $11.5 million in equity and convertible notes.

• Net losses: $2.2 million (2024), $1.4 million (2025), $475,000 (Q1 2026); accumulated deficit of $11.3 million as of March 31, 2026.

• Cash and cash equivalents: $251,000 as of March 31, 2026; company expects IPO proceeds plus existing cash to fund operations into the future but not through regulatory approval.

• Operating expenses primarily for R&D and G&A; research and development expenses expected to increase as clinical programs advance.

Use of proceeds and capital allocation

• Net proceeds from IPO to fund continued development of mizagliflozin for PBH and gastroparesis, pay accrued expenses, support additional R&D, and for general corporate purposes.

• A portion may be used for in-licensing, acquisitions, or investments in complementary businesses or technologies.

• Proceeds are not expected to be sufficient to fund any product candidate through regulatory approval; additional capital will be required.